| Date Filed | Type | Description |
| 03/31/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/10/2017 |
SC 13G/A
| Ignyta, Inc. reports a 6.8% stake in IGNYTA, INC. |
| 02/10/2012 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 01/26/2012 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 12/21/2011 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement |
| 12/21/2011 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/21/2011 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/21/2011 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/21/2011 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/21/2011 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 12/21/2011 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 11/14/2011 |
SC 13D
| Grace 2, Inc. has filed a Schedule 13D for Q HOLDINGS, INC. |
| 10/19/2011 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)] |
| 10/14/2011 |
8-K
| Quarterly results |
| 10/14/2011 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 10/11/2011 |
8-K
| Form 8-K - Current report |
| 09/30/2011 |
8-K
| Other Events |
| 09/26/2011 |
8-K
| Other Events |
| 09/09/2011 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 08/22/2011 |
8-K
| Form 8-K - Current report |
| 08/22/2011 |
PRN
| Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015 |
| 08/03/2011 |
10-Q
| Quarterly Report for the period ended June 30, 2011 |
| 08/02/2011 |
8-K
| Quarterly results |
| 07/21/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 07/21/2011 |
PRN
| Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ |
| 07/14/2011 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 06/29/2011 |
8-K
| Form 8-K - Current report |
| 06/29/2011 |
PRN
| Cephalon to Release Second Quarter 2011 Earnings Results After the Market Close on August 2, 2011 |
| 06/28/2011 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/23/2011 |
11-K
| Form 11-K - Annual report of employee stock purchase, savings and similar plans |
| 06/13/2011 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 05/27/2011 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition |
| 05/24/2011 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Eighth Amendment to the Credit Agreement among Cephalon, Inc., the lenders named therein, JPMorgan Chase Bank, N.A., as administrative agent, Deutsche Bank Securities Inc. and Bank of America N.A., as co-syndication agents, Wachovia Bank, N.A. and Barclays Bank plc, as co-documentation agents, and J.P. Morgan Securities Inc., Deutsche Bank Securities Inc. and Banc of America Securities LLC, as joint bookrunners and joint lead arrangers",
"Cephalon to declare recommended ChemGenex Offers unconditional on reaching 90% under each Offer 20 May 2011 — Cephalon CXS Holdings Pty Ltd today provided an update on the status of its cash offers for ChemGenex Shares and ChemGenex Listed Options. The aggregate of the Cephalon Group's existing shareholding in ChemGenex, acceptances of the Share Offer and acceptances in the Institutional Acceptance Facility now represents approximately 78.01% of all ChemGenex Shares on issue. Cephalon also has a relevant interest in 86.40% of all ChemGenex Listed Options on issue. Cephalon has confirmed that, if:",
"Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation" |
|
| 05/20/2011 |
PRN
| Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation |
|